DocStoX is a free AI-powered research platform for Indian equity markets, covering 6,800+ NSE & BSE stocks with prices, fundamentals, 326 financial ratios, shareholding, FII/DII flows, F&O, IPOs, a visual screener and AI stock scoring.

Yes. DocStoX has a free tier covering stock research, the screener, FII/DII data and educational guides, plus a free MCP API tier (50 tool calls/day) for AI assistants. A Pro plan adds higher limits and advanced features.

What data does DocStoX cover?

Every NSE & BSE listed stock (6,800+ instruments): EOD and intraday prices, income statement / balance sheet / cash flow, 326 ratios, quarterly shareholding, promoter pledge, mutual-fund holdings, FII/DII flows, F&O and option-chain data, analyst forecasts, IPOs, corporate actions and news.

Can AI assistants like ChatGPT or Claude use DocStoX data?

Yes. DocStoX runs a public Model Context Protocol (MCP) server at https://mcp.docstox.com/mcp with 39 tools, so Claude, ChatGPT, Cursor and other MCP clients can pull Indian market data directly. Setup and a free key are at https://docstox.com/mcp.

What is the PE ratio of Astonea Labs Ltd?

Astonea Labs Ltd has a price-to-earnings (PE) ratio of 64.4 in the Healthcare sector.

What is the market capitalisation of Astonea Labs Ltd?

Astonea Labs Ltd has a market capitalisation of approximately ₹291 crore.

Astonea Labs Ltd

ASTONEALABSLTD·NSE·Healthcare

₹0.00▲ +0.00 (+0.00%)

⚠️Trading suspended. Not a live price.

Healthcare · Pharmaceuticals

A steady, established business

52W₹118

₹301-64%

Open

—

High

—

Low

—

Prev Close

—

Volume

—

VWAP

—

Snapshot

Key fundamentals

Market Cap

₹291 Cr

P/E Ratio

64.40Expensive

P/B Ratio

5.10

EPS

₹6.93

Book Value

₹54.35

ROE

12.00%Average

ROCE

17.00%Decent

Dividend Yield

0.00%

Debt / Equity

0.74Moderate

Face Value

₹10.00

52W High

₹301.30

52W Low

₹118.00

Sector

Healthcare

Industry

Pharmaceuticals

Fairly Valued

Narrow moatMedium uncertainty

Fair value estimate

₹102

No recent traded price

BearFair valueBull

₹73₹102₹117

/100

Business quality — Watch the fundamentals

Growth 50Profitability 26Efficiency 45Valuation 32

Plain English

Our view

A steady, established business
Promoters hold a controlling stake
Expensive — trades at 64× earnings

How we got there

Fair value methods

Residual income

29% ROE fading to 13% over ~10 yrs, on ₹54 book

₹110

Relative P/E

Needs ≥3 peers with P/E

—

Graham floor

Conservative floor: √(22.5 × EPS × book value/share)

₹73

Analyst target

No analyst coverage

—

Blended fair value₹102

What the numbers say

Investment thesis

Bull case

Promoters hold a controlling stake

Bear case

Expensive — trades at 64× earnings

Free — see our deterministic Fair Value range, business quality score, and the full bull/bear case for this stock.

Snapshot

Key statistics

P/E

64.4Expensive

Below 15× is value territory; above 35× prices in strong growth

ROE

12.0%Average

Above 15% is considered healthy for Indian equities

ROCE

17.0%Decent

Above 18% means capital is working hard

Debt/Eq

0.74Moderate

Below 0.5 is comfortable; above 1.5 strains the balance sheet

Mkt Cap

₹291 Cr

P/B

5.10

EPS

₹6.93

Div Yield

—

What changed

Recent changes

Foreign investors-2.5% stake last quarter
Domestic institutions-0.3% stake last quarter

What matters

News impact

Overview

Valuation

Expensive

P/E 64.4×

Growth

Strong

+30% rev CAGR

Profitability

Healthy

12.0% ROE

Financial health

Comfortable

D/E 0.74

Momentum

N/A

No technicals

Today

Trading activity

Delivery %—

Turnover—

Trades—

VWAP—

Face value₹10.00

Market depth

Market depth available during market hours

Snapshot

Technical signals

Compounded annual growth

Growth (CAGR)

Revenue

+30.1%

—

10Y

—

Profit

+57.8%

—

10Y

—

EPS

+36.8%

—

10Y

—

Profile

Cons

Stock is trading at 5.20 times its book value
Though the company is reporting repeated profits, it is not paying out dividend
Company might be capitalizing the interest cost
Working capital days have increased from 43.9 days to 74.2 days

Forecast

News

Peers

Financials

Growth

Shareholding

Ownership

Ownership breakdown

Quarter ending 31 Mar 2026

Foreign investors sold 2.51 pts; domestic institutions reduced 0.28 pts last quarter. The QoQ column shows each group's change versus the prior quarter.

72%

Promoter

Promoters

72.3%0.00

Public

22.3%+5.19

FII / FPI

0.0%-2.51

DII

0.1%-0.28

Others

5.4%

Total shareholders

376-61 QoQ

Quarterly trend

Ownership over time

Q4 FY26

Promoter72.30%

DII0.07%

Public22.25%

Others5.38%

Corporate Actions

Bulk & Block Deals

Filings

MF Holdings

Technicals

FAQs

Quick reference

Frequently asked questions

Incorporated in 2017, Astonea Labs Ltd. is engaged in contract manufacturing of pharmaceutical and cosmetic products for companies[1]

Astonea Labs Ltd valuation & research

Deep-dive tools with DocStoX's fair-value estimate, ratios and peers.

Fair Value Intrinsic Value DCF Valuation Financial Ratios Peers

Astonea Labs Ltd peers in Healthcare

Other Healthcare stocks on the NSE & BSE. See the full Healthcare sector list.

SUN PHARMACEUTICAL IND L DIVI S LABORATORIES LTD TORRENT PHARMACEUTICALS L APOLLO HOSPITALS ENTER. L ZYDUS LIFESCIENCES LTD CIPLA LTD LUPIN LIMITED MAX HEALTHCARE INS LTD MANKIND PHARMA LIMITED DR. REDDY S LABORATORIES AUROBINDO PHARMA LTD LAURUS LABS LIMITED

Compare Astonea Labs Ltd with peers

Astonea Labs Ltd vs SUN PHARMACEUTICAL IND L Astonea Labs Ltd vs DIVI S LABORATORIES LTD Astonea Labs Ltd vs TORRENT PHARMACEUTICALS L Astonea Labs Ltd vs APOLLO HOSPITALS ENTER. L Astonea Labs Ltd vs ZYDUS LIFESCIENCES LTD Astonea Labs Ltd vs CIPLA LTD

Astonea Labs Ltd

Key fundamentals

Key statistics

Recent changes

News impact

Overview

Trading activity

Technical signals

Growth (CAGR)

Company information

Cons

Forecast

News

Peers

Financials

Growth

Shareholding

Ownership breakdown

Ownership over time

Corporate Actions

Bulk & Block Deals

Filings

MF Holdings

Technicals

FAQs

Frequently asked questions

Astonea Labs Ltd valuation & research

Astonea Labs Ltd peers in Healthcare

Compare Astonea Labs Ltd with peers

Key statistics

Recent changes

News impact

Trading activity

Technical signals

Growth (CAGR)

Company information

Cons

Ownership breakdown

Ownership over time

Frequently asked questions